Infantile colic is a frustrating impasse that affects up to 20% of infants. Nevertheless, its pathogenesis is currently unknown, some hypotheses are food hypersensitivity or allergy, gut dysmotility, inflammation, and visceral pain. Probiotics use in treatment and prevention of infantile colic is a moderately new topic. Moreover, Probiotics strains exhibit a wide range of health benefits by modifying the intestinal microbiota and immunity. Lactobacillus reuteri is one of the utmost widely studied probiotic strains. It endorses gut health by stimulation of mucosal gut barrier functions, production of antimicrobial substances (such as reuterin and lactic acid) and influencing acquired and innate immune responses. Reuterin produced by L. reuteri is a potent anti-microbial compound capable of inhibiting a wide spectrum of pathogenic microorganisms. L. reuteri creates biofilms that stimulate tumor necrosis factor production by lipopolysaccharide (LPS)-activated monocytoid cells, apart from antimicrobial metabolite production. Interestingly, as a potential therapy for childhood, L. reuteri administration has emerged functional gastrointestinal disturbances as these disturbances are associated with gut microbiota perturbations in early life. The review précises the beneficial aspects of the probiotic L. reuteri strain in clinical practice with a special focus on its role in improving gut health and immunity including managing Infantile colic in infants and toddlers.
| Published in | American Journal of Pediatrics (Volume 9, Issue 3) |
| DOI | 10.11648/j.ajp.20230903.17 |
| Page(s) | 140-149 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Lactobacillus Reuteri, Infantile Colic, Functional Gastrointestinal
| [1] | Roberts DM, Ostapchuk M, O brien JG. Infantile colic. Am Fam Physician. 2004; 70: 735-40. [PubMed] [Google Scholar]. |
| [2] | Hide DW, Guyer BM. Prevalence of infant colic. Arch Dis Child. 1982; 57: 559-60. [PubMed] [Google Scholar]. |
| [3] | Wessel MA, Cobb JC, Jackson EB, Harris GS, Detwiler AC. Paroxysmal fussing in infancy, sometimes called "colic". Pediatrics. 1954; 14: 421-35. [PubMed] [Google Scholar]. |
| [4] | Pärtty A, Lehtonen L, Kalliomäki M, Salminen S, Isolauri E. Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. Pediatr Res. 2015; 78: 470. [PubMed] [Google Scholar]. |
| [5] | Brazelton TB. Crying in infancy. Pediatrics. 1962; 29: 579-88. [PubMed] [Google Scholar]. |
| [6] | Illingworth RS. Infantile colic revisited. Arch Dis Child. 1985; 60: 981-5. ] [PubMed] [Google Scholar]. |
| [7] | Leung AKC, Lemay JF. Infantile colic: a review. J R Soc Promot Health. 2004; 124: 162–6. [PubMed] [Google Scholar]. |
| [8] | Romanello S, Spiri D, Marcuzzi E, Zanin A, Boizeau P, Riviere S, et al. Association between childhood migraine and history of infantile colic. JAMA. 2013; 309: 1607-12. [PubMed] [Google Scholar]. |
| [9] | Savino F, Tarasco V. New treatments for infant colic. CurrOpinPediatr. 2010; 22: 791-7. [PubMed] [Google Scholar]. |
| [10] | Savino F, Clara Grassino E, Guidi C, Oggero R, Silvestro L, Miniero R. Ghrelin and motilin concentration in colicky infants. Acta Paediatr. 2006; 95: 738-41. [PubMed] [Google Scholar]. |
| [11] | Pärtty A, Kalliomäki M, Salminen S, Isolauri E. Infantile colic is associated with low-grade systemic inflammation. J Pediatr Gastroenterol Nutr. 2017; 64: 691–5. [PubMed] [Google Scholar]. |
| [12] | Sarasu JM, Narang M, Shah D. Infantile colic: an update. Indian Pediatr. 2018; 55: 979–87. [PubMed] [Google Scholar]. |
| [13] | Wade S, Kilgour T. Infantile colic. BMJ. 2001; 323: 437-40. [PubMed] [Google Scholar]. |
| [14] | Danielsson B, Hwang CP. Treatment of infantile colic with surface active substance (simethicone) Acta Paediatr Scand. 1985; 74: 446-50. [PubMed] [Google Scholar]. |
| [15] | Metcalf TJ, Irons TG, Sher LD, Young PC. Simethicone in the treatment of infant colic: a randomized, placebo-controlled, multicenter trial. Pediatrics. 1994; 94: 29-34. [PubMed] [Google Scholar]. |
| [16] | Goldman MH. Dicycloverine for persistent crying in babies: dicycloverine is contraindicated in infants. BMJ. 2004; 328: 956-7. [PubMed] [Google Scholar]. |
| [17] | Biagioli E, Tarasco V, Lingua C, Moja L, Savino F. Pain-relieving agents for infantile colic. Cochrane Database Syst Rev. 2016; 9: CD009999. [PubMed] [Google Scholar]. |
| [18] | FAO/WHO Working Group. Ontario (Canada): FAO/WHO Working Group; 2002. Guidelines for the evaluation of probiotic in food [Internet] [cited 2020 Feb 25]. Available from: https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. [Google Scholar]. |
| [19] | Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125: 1401-2. [PubMed] [Google Scholar]. |
| [20] | Soccol CR, VandenbergheLPdS, Spier MR, Medeiros ABP, Yamaguishi CT, Lindner JDD, et al. The potential of probiotics: a review. Food Technol Biotech. 2010; 48: 413-34. [Google Scholar]. |
| [21] | Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis. 2008; 14: 1068–83. [PubMed] [Google Scholar]. |
| [22] | Bashashati M, Rezaei N, Shafieyoun A, McKernan DP, Chang L, Öhman L, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. NeurogastroenterolMotil. 2014; 26: 1036-48. [PubMed] [Google Scholar]. |
| [23] | Pike BL, Paden KA, Alcala AN, Jaep KM, Gormley RP, Maue AC, et al. Immunological biomarkers in postinfectious irritable bowel syndrome. J Travel Med. 2015; 22: 242-50. [PubMed] [Google Scholar]. |
| [24] | Darkoh C, Comer L, Zewdie G, Harold S, Snyder N, Dupont HL. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One. 2014; 9: e93144. [PubMed] [Google Scholar]. |
| [25] | Rhoads JM, Fatheree NY, Norori J, Liu Y, Lucke JF, Tyson JE, et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J Pediatr. 2009; 155: 823-8. e821. [PubMed] [Google Scholar]. |
| [26] | Savino F, Garro M, Montanari P, Galliano I, Bergallo M. Crying time and RORγ/FOXP3 expression in Lactobacillus reuteri DSM17938-treated infants with colic: a randomized trial. J Pediatr. 2018; 192: 171-7. e171. [PubMed] [Google Scholar]. |
| [27] | Kim CH. FOXP3 and its role in the immune system. Adv Exp Med Biol. 2009; 665: 17-29. [PubMed] [Google Scholar]. |
| [28] | Kianifar H, Ahanchian H, Grover Z, Jafari S, Noorbakhsh Z, Khakshour A, et al. Synbiotic in the management of infantile colic: a randomised controlled trial. J Paediatr Child Health. 2014; 50: 801-5. [PubMed] [Google Scholar]. |
| [29] | Mi GL, Zhao L, Qiao DD, Kang WQ, Tang MQ, Xu JK. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek. 2015; 107: 1547-53. [PubMed] [Google Scholar]. |
| [30] | Savino F, Galliano I, Savino A, Daprà V, Montanari P, Calvi C, et al. Lactobacillus reuteri DSM 17938 probiotics may increase CC-chemokine receptor 7 expression in infants treated with for colic. Front Pediatr. 2019; 7: 1-7. [PubMed] [Google Scholar]. |
| [31] | Gerasimov S, Gantzel J, Dementieva N, Schevchenko O, Tsitsura O, Guta N, et al. Role of Lactobacillus rhamnosus (FloraActive™) 19070-2 and Lactobacillus reuteri (FloraActive™) 12246 in infant colic: a randomized dietary study. Nutrients. 2018; 10: 1975. [PubMed] [Google Scholar]. |
| [32] | Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014; 348: g2107. [PubMed] [Google Scholar]. |
| [33] | Ashraf MW, Ayaz SB, Ashraf MN, Matee S, Shoaib M. Probiotics are effective in alleviating infantile colic; results of a randomized controlled trial held at Benazir Bhutto hospital, Rawalpindi, Pakistan. RMJ. 2015; 40: 277-80. [Google Scholar]. |
| [34] | Giglione E, Prodam F, Bellone S, Monticone S, Beux S, Marolda A, et al. The association of Bifidobacterium breve BR03 and B632 is effective to prevent colics in bottle-fed infants: a pilot, controlled, randomized, and double-blind study. J Clin Gastroenterol. 2016; 50: S164-7. [PubMed] [Google Scholar]. |
| [35] | Baldassarre ME, Di Mauro A, Tafuri S, Rizzo V, Gallone MS, Mastromarino P, et al. Effectiveness and safety of a probiotic-mixture for the treatment of infantile colic: a double-blind, randomized, placebo-controlled clinical trial with fecal real-time PCR and NMR-based metabolomics analysis. Nutrients. 2018; 10: 195. 1-13. [PubMed] [Google Scholar]. |
| [36] | Shen JM, Feng L, Feng C. Role of mtDNA haplogroups in the prevalence of osteoarthritis in different geographic populations: a meta-analysis. PLoS One. 2014; 9: e108896. [PubMed] [Google Scholar]. |
| [37] | Skonieczna-Żydecka K, Janda K, Kaczmarczyk M, Marlicz W, Łoniewski I, Łoniewska B. The effect of probiotics on symptoms, gut microbiota and inflammatory markers in infantile colic: a systematic review, meta-analysis and meta-regression of randomized controlled trials. J Clin Med. 2020; 9: 1-21. [PubMed] [Google Scholar]. |
| [38] | Xu M, Wang J, Wang N, Sun F, Wang L, Liu XH. The efficacy and safety of the probiotic bacterium Lactobacillus reuteri DSM 17938 for infantile colic: a meta-analysis of randomized controlled trials. PLoS One. 2015; 10: e0141445. [PubMed] [Google Scholar]. |
| [39] | Sung V, Collett S, de Gooyer T, Hiscock H, Tang M, Wake M. Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis. JAMA Pediatrics. 2013; 167: 1150-7. [PubMed] [Google Scholar]. |
| [40] | Gutiérrez-Castrellón P, Indrio F, Bolio-Galvis A, Jiménez-Gutiérrez C, Jimenez-Escobar I, López-Velázquez G. Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: systematic review with network meta-analysis. Medicine. 2017; 96: e9375–5. [PubMed] [Google Scholar]. |
| [41] | Rahimi VB, Askari VR, Shirazinia R, Soheili-Far S, Askari N, RahmanianDevin P, et al. Protective effects of hydro-ethanolic extract of Terminalia chebula on primary microglia cells and their polarization (M1/M2 balance) MultSclerRelatDisord. 2018; 25: 5-13. [PubMed] [Google Scholar]. |
| [42] | Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017; 9: 7204-18. [PubMed] [Google Scholar]. |
| [43] | Fatheree NY, Liu Y, Ferris M, Van Arsdall M, McMurtry V, Zozaya M, et al. Hypoallergenic formula with Lactobacillus rhamnosus GG for babies with colic: a pilot study of recruitment, retention, and fecal biomarkers. World J GastrointestPathophysiol. 2016; 7: 160-70. [PubMed] [Google Scholar]. |
| [44] | Rhoads JM, Collins J, Fatheree NY, Hashmi SS, Taylor CM, Luo M, et al. Infant colic represents gut inflammation and dysbiosis. J Pediatr. 2018; 203: 55-61. e53. [PubMed] [Google Scholar]. |
| [45] | Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatrica. 2002; 91: 45-50. [PubMed] [Google Scholar]. |
| [46] | Sung V, Cabana MD. Probiotics for colic-is the gut responsible for infant crying after all? J Pediatr. 2017; 191: 6-8. [PubMed] [Google Scholar]. |
| [47] | Røseth A, Fagerhol M, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol. 1992; 27: 793-8. [PubMed] [Google Scholar]. |
| [48] | Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997; 58: 176-80. [PubMed] [Google Scholar]. |
APA Style
Sukhamoy Kangsha Banik, Mahmuda Zaman, Muhammad Rezaul Karim, Mohammed Mahfuzur Rahman, Ahmed Nazmul Anam, et al. (2023). Efficacy of Lactobacillus Reuteri in Improving Gut Barrier Function & Management of Infantile Colic. American Journal of Pediatrics, 9(3), 140-149. https://doi.org/10.11648/j.ajp.20230903.17
ACS Style
Sukhamoy Kangsha Banik; Mahmuda Zaman; Muhammad Rezaul Karim; Mohammed Mahfuzur Rahman; Ahmed Nazmul Anam, et al. Efficacy of Lactobacillus Reuteri in Improving Gut Barrier Function & Management of Infantile Colic. Am. J. Pediatr. 2023, 9(3), 140-149. doi: 10.11648/j.ajp.20230903.17
AMA Style
Sukhamoy Kangsha Banik, Mahmuda Zaman, Muhammad Rezaul Karim, Mohammed Mahfuzur Rahman, Ahmed Nazmul Anam, et al. Efficacy of Lactobacillus Reuteri in Improving Gut Barrier Function & Management of Infantile Colic. Am J Pediatr. 2023;9(3):140-149. doi: 10.11648/j.ajp.20230903.17
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajp.20230903.17,
author = {Sukhamoy Kangsha Banik and Mahmuda Zaman and Muhammad Rezaul Karim and Mohammed Mahfuzur Rahman and Ahmed Nazmul Anam and Hasan Al Zami and Farzana Rahman Chowdhury},
title = {Efficacy of Lactobacillus Reuteri in Improving Gut Barrier Function & Management of Infantile Colic},
journal = {American Journal of Pediatrics},
volume = {9},
number = {3},
pages = {140-149},
doi = {10.11648/j.ajp.20230903.17},
url = {https://doi.org/10.11648/j.ajp.20230903.17},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20230903.17},
abstract = {Infantile colic is a frustrating impasse that affects up to 20% of infants. Nevertheless, its pathogenesis is currently unknown, some hypotheses are food hypersensitivity or allergy, gut dysmotility, inflammation, and visceral pain. Probiotics use in treatment and prevention of infantile colic is a moderately new topic. Moreover, Probiotics strains exhibit a wide range of health benefits by modifying the intestinal microbiota and immunity. Lactobacillus reuteri is one of the utmost widely studied probiotic strains. It endorses gut health by stimulation of mucosal gut barrier functions, production of antimicrobial substances (such as reuterin and lactic acid) and influencing acquired and innate immune responses. Reuterin produced by L. reuteri is a potent anti-microbial compound capable of inhibiting a wide spectrum of pathogenic microorganisms. L. reuteri creates biofilms that stimulate tumor necrosis factor production by lipopolysaccharide (LPS)-activated monocytoid cells, apart from antimicrobial metabolite production. Interestingly, as a potential therapy for childhood, L. reuteri administration has emerged functional gastrointestinal disturbances as these disturbances are associated with gut microbiota perturbations in early life. The review précises the beneficial aspects of the probiotic L. reuteri strain in clinical practice with a special focus on its role in improving gut health and immunity including managing Infantile colic in infants and toddlers.},
year = {2023}
}
TY - JOUR T1 - Efficacy of Lactobacillus Reuteri in Improving Gut Barrier Function & Management of Infantile Colic AU - Sukhamoy Kangsha Banik AU - Mahmuda Zaman AU - Muhammad Rezaul Karim AU - Mohammed Mahfuzur Rahman AU - Ahmed Nazmul Anam AU - Hasan Al Zami AU - Farzana Rahman Chowdhury Y1 - 2023/07/31 PY - 2023 N1 - https://doi.org/10.11648/j.ajp.20230903.17 DO - 10.11648/j.ajp.20230903.17 T2 - American Journal of Pediatrics JF - American Journal of Pediatrics JO - American Journal of Pediatrics SP - 140 EP - 149 PB - Science Publishing Group SN - 2472-0909 UR - https://doi.org/10.11648/j.ajp.20230903.17 AB - Infantile colic is a frustrating impasse that affects up to 20% of infants. Nevertheless, its pathogenesis is currently unknown, some hypotheses are food hypersensitivity or allergy, gut dysmotility, inflammation, and visceral pain. Probiotics use in treatment and prevention of infantile colic is a moderately new topic. Moreover, Probiotics strains exhibit a wide range of health benefits by modifying the intestinal microbiota and immunity. Lactobacillus reuteri is one of the utmost widely studied probiotic strains. It endorses gut health by stimulation of mucosal gut barrier functions, production of antimicrobial substances (such as reuterin and lactic acid) and influencing acquired and innate immune responses. Reuterin produced by L. reuteri is a potent anti-microbial compound capable of inhibiting a wide spectrum of pathogenic microorganisms. L. reuteri creates biofilms that stimulate tumor necrosis factor production by lipopolysaccharide (LPS)-activated monocytoid cells, apart from antimicrobial metabolite production. Interestingly, as a potential therapy for childhood, L. reuteri administration has emerged functional gastrointestinal disturbances as these disturbances are associated with gut microbiota perturbations in early life. The review précises the beneficial aspects of the probiotic L. reuteri strain in clinical practice with a special focus on its role in improving gut health and immunity including managing Infantile colic in infants and toddlers. VL - 9 IS - 3 ER -
Information
Email: